Published: Tuesday, December 06, 2011 Last Updated: Tuesday, December 06, 2011
Astra Biotech GmbH is in the pre-launch phase of its newly developed test, based on microarray technology, for rapid simultaneous detection of 25 of the most common mutations causing cystic fibrosis in pan-European populations.
Full access to this article is for registered users only. Registration is free-of-charge and allows access to all content on our web communities.
Already registered? Then please log in at the top of the page.